AZD 6765

Drug Profile

AZD 6765

Alternative Names: [14C]AZD6765; AZD-6765

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 31 Dec 2013 Discontinued - Phase-I for Major depressive disorder in United Kingdom (IV)
  • 31 Dec 2013 Discontinued - Phase-I for Major depressive disorder in USA (PO)
  • 31 Dec 2013 Discontinued - Phase-II for Major depressive disorder in Chile (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top